{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:39:53Z","timestamp":1759541993172},"reference-count":20,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2008,3,10]],"date-time":"2008-03-10T00:00:00Z","timestamp":1205107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2008,5]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>In resource\u2010limited countries, stavudine (d4T) is commonly used as part of the initial highly active antiretroviral therapy (HAART) regimen. Many patients who subsequently develop lipodystrophy switch from d4T to zidovudine (ZDV), a drug that can be myelotoxic. We aimed to study the spectrum and severity of haematological changes following this substitution.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a retrospective cohort study. The inclusion criteria were as follows: HIV\u2010infected children were included who (1) were 2\u201315 years old at the time of HAART initiation, (2) had not been diagnosed as having haematological diseases, (3) had been receiving a first HAART regimen consisting of either nevirapine or efavirenz, together with lamivudine and d4T, for at least 48 weeks and (4) had switched from d4T to ZDV at least 48 weeks previously.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seventy\u2010eight children were included in the study. Thirty\u2010six (46%) were male. The mean age was 10.3 years (standard deviation 3.1 years). The switch had been made a median time of 65 weeks (range 48\u201397 weeks) previously. There was no significant change in CD4 lymphocyte count or percentage, or HIV RNA level, after the switch. There was a statistically significant decrease in haemoglobin level (12.6 <jats:italic>vs.<\/jats:italic>12.1\u2003g\/dL; <jats:italic>P<\/jats:italic>&lt;0.001), total white blood cell (WBC) count (8088 <jats:italic>vs.<\/jats:italic> 6910\u2003cells\/\u03bcL; <jats:italic>P<\/jats:italic>&lt;0.001) and absolute neutrophil count (ANC) (4320 <jats:italic>vs.<\/jats:italic> 3448\u2003cells\/\u03bcL; <jats:italic>P<\/jats:italic>&lt;0.001). However, the decreases never reached Division of AIDS grade 3 or 4 severity, and none of the patients had clinical symptoms or signs of anaemia, leukopenia, or neutropenia. No participant had to discontinue ZDV during the 48\u2010week follow\u2010up period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In a paediatric population, statistically significant decreases in haemoglobin level, WBC count and ANC occurred following the substitution of d4T with ZDV, but the magnitudes of the decreases were small and not clinically significant.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2008.00560.x","type":"journal-article","created":{"date-parts":[[2008,3,11]],"date-time":"2008-03-11T03:24:14Z","timestamp":1205205854000},"page":"317-321","source":"Crossref","is-referenced-by-count":13,"title":["Haematological changes after switching from stavudine to zidovudine in HIV\u2010infected children receiving highly active antiretroviral therapy"],"prefix":"10.1111","volume":"9","author":[{"given":"L","family":"Aurpibul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Puthanakit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Sirisanthana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Sirisanthana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,4,7]]},"reference":[{"key":"e_1_2_6_2_2","unstructured":"UNAIDS\/WHO.AIDS epidemic update: December 2007. Available fromhttp:\/\/www.unaids.org\/en\/default.asp[Accessed 6 December 2007]."},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/430714"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/510489"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318125720a"},{"key":"e_1_2_6_6_2","unstructured":"WHOantiretroviral therapy of HIV infection in infants and children in resource\u2010limited settings: towards universal access. Recommendations for a public health approach 2006. Available fromhttp:\/\/www.who.int\/hiv\/pub\/guidelines\/art\/en\/index.html[Accessed 6 December 2007]."},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1179\/146532806X107467"},{"key":"e_1_2_6_8_2","unstructured":"KosalaraksaP EngchanilC PuthanakitTet al. Prevalence of anemia and impact of iron status in HIV\u2010infected children with moderate immunosuppression.4th IAS Conference on HIV Pathogenesis Treatment and Prevention. Sydney Australia 2007 [Abstract no. TUPEB137]."},{"key":"e_1_2_6_9_2","first-page":"333","article-title":"Haematologic features of the human immunodeficiency virus (HIV) infection in black children in Harare","volume":"40","author":"Adewuyi J","year":"1994","journal-title":"Cent Afr J Med"},{"key":"e_1_2_6_10_2","first-page":"713","article-title":"Antiretroviral therapy in HIV\u2010infected children","volume":"19","author":"Leonard EG","year":"2005","journal-title":"the metabolic cost of improved survival"},{"key":"e_1_2_6_11_2","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1177\/135965350701200811","article-title":"Lipodystrophy and metabolic changes in HIV\u2010infected children on non\u2010nucleoside reverse transcriptase inhibitor\u2010based antiretroviral therapy","volume":"12","author":"Aurpibul L","year":"2007","journal-title":"Antiviral Ther"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200501030-00002"},{"key":"e_1_2_6_13_2","unstructured":"Centers for Disease Control and Prevention.1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. Official authorized addenda: human immunodeficiency virus infection codes and official guidelines for coding and reporting ICD\u20109\u2010CM.Morb Mortal Wkly Rep1994;43(RR\u201012):1\u201319."},{"key":"e_1_2_6_14_2","unstructured":"The Division of AIDS.Table for Grading the Severity of Adult and Pediatric Adverse Events Version 1.0 December 2004.http:\/\/www3.niaid.nih.gov\/research\/resources\/DAIDSClinRsrch\/PDF\/Safety\/DAIDSAEGradingTable.pdf[Accessed 6 December 2007]."},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-200111010-00003"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199905280-00010"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/313714"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910143411617"},{"key":"e_1_2_6_19_2","first-page":"337","volume-title":"2007 Medical Management of HIV Infection","author":"Bartlett JG","year":"2007"},{"key":"e_1_2_6_20_2","unstructured":"ToeungPD PouvS ChelSet al. Routine switch after 6 months from d4T to AZT containing antiretroviral therapy at an outpatient HIV clinic in Phnom Penh Cambodia.4th IAS conference on HIV pathogenesis treatment and prevention. Sydney Australia 2007 [Abstract no. WEPEB059]."},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2007.00498.x"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2008.00560.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2008.00560.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T18:55:11Z","timestamp":1696877711000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2008.00560.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,7]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["10.1111\/j.1468-1293.2008.00560.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2008.00560.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,7]]}}}